Ivabradine Impurity 35
 
		Product Description
CAT No.
				
									ALN-I014067								
				CAS No.
				
									NA								
				Mol. F.
				
									C27H37ClN2O5 : HCl								
				Mol. Wt.
				
									505.1 : 36.5								
				Stock
				
									Please Inquire								
				
										
							
										Product Overview
						
											
										
							
										Technical Data
						
											
										
							
										Reference
						
											
										
							
										RFQ
						
									
							
							
							Product Overview
			
						
									Chemical Name : 3-(3-((3-Chloro-2-(3,4-dimethoxyphenyl)propyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one, hydrochloride (1:1)								
				
									Smiles : O=C1N(CCCN(CC(C2=CC=C(OC)C(OC)=C2)CCl)C)CCC3=CC(OC)=C(OC)C=C3C1.Cl								
				
									Inchi : InChI=1S/C18H19N3O7S/c1-8-7-29-16-12(15(23)21(16)13(8)17(24)25)20-14(22)11(19)9-3-5-10(6-4-9)28-18(26)27-2/h3-6,11-12,16H,7,19H2,1-2H3,(H,20,22)(H,24,25)/t11-,12-,16-/m1/s1								
				
							
							
							Technical Data
			
						
							
							
							Reference
			
						Forced Degradation Studies of Ivabradine and In Silico Toxicology Predictions for Its New Designated Impurities
									Piotr Pikul,1 Marzena Jamru00f3giewicz,1,* Joanna Nowakowska,1 Weronika Hewelt-Belka,2,3 and Krzesimir CiuranFront Pharmacol. 2016; 7: 117.								
				Simultaneous determination of chiral and achiral impurities of ivabradine on a cellulose tris(3-chloro-4-methylphenylcarbamate) chiral column using polar organic mode
									 Joanna Nowakowska,1 Weronika Hewelt-Belka,2,3 and Krzesimir Ciura – Front Pharmacol. 2016; 7: 117. 								
				Characterization of degradation products of Ivabradine by LC-HR-MS/MS: a typical case of exhibition of different degradation behaviour in HCl and H2SO4 acid hydrolysis
									ElekFerenczabBélaKovácsabFranciscBodaaMohammadhassanForoughbakhshfasaeicÉva KatalinKelemenbGerg?TóthcZoltán-IstvánSzabó – Journal of Pharmaceutical and Biomedical Analysis Volume 177, 5 January 2020, 112851 								
				
							
							
							RFQ
			
						
 
                             
                             
                             
                             
                            